- OptiPEAK T Lymphocyte XPR Expansion of T Cells without Serum in Chemically Defined Media
OptiPEAK T Lymphocyte XPR Expansion of T Cells without Serum in Chemically Defined Media
Published on 16 December 2021
Atherly Pennybaker, Media Formulation and Product Applications Specialist, InVitria
Combine supplements of OptiPEAK T Lymphocyte XPR media. Isolate human T lymphocytes from whole blood. Wash to remove traces of donor serum. Activate and expand T lymphocytes (7-10 days) in OptiPEAK T Lymphocyte XPR serum free media. Harvest T lymphocytes. Perform post- expansion, flow cytometric analysis of phenotypic surface markers.
Human T Cell expansion has become an increasingly important tool in the development of both autologous and allogeneic immunotherapies, as T cells emerge as an exciting option to treat a wide range of diseases. Major components used to expand these cells include human and bovine serum, as well as proteins derived from these substances. These components not only have the potential to introduce harmful pathogens to the already compromised patient in a clinical setting, but they also have significant limitations in the ability to ensure robust and reproducible performance in cell culture systems. Even so-called “xeno-free” media—often confused with chemically defined, animal-component-free media—contain proteins derived from human or bovine serum. OptiPEAK T Lymphocyte XPR media (product No. 555CDK0045-1L) supports the growth and expansion of human primary T cells and contains only synthetic and recombinant components. This medium is considered blood-free and all components are chemically defined, providing robust performance without compromising growth, safety, or phenotype [1,2,3].
Growth Media Preparation
- OptiPEAK T Lymphocyte XPR media (product No. 555CDK0045-1L)
- Components: Base Media, 10X Protein Supplement
- Gentamicin/amphotericin B (Life Technologies #R01510)
- RPMI-medium with Glutamax
- Fetal Bovine Serum (FBS)
- Human Serum (HS)
Plate Set Up
- 12-Well flat-bottom sterile plates with lids
- 6-Well flat-bottom sterile plates with lids
Human T-Lymphocyte Isolation
- Human whole blood from 2 or more normal healthy donors
- Human T Cell Enrichment Cocktail (Stem Cell Technologies #15061) Density Gradient (StemCell Technologies #07801)
- Dulbecco’s Phosphate Buffered Saline (dPBS)
Activation of T-Lymphocytes
- Human T-Activator CD3/CD28 beads (Life Technologies 11141D)
- Recombinant Human IL-2 (Peprotech 200-02)
Flow Cytometry Analysis
- Harvest antibodies, mouse
- CD8, PE labeled
- CD4, FITC labeled
- Centrifuge and 50 mL conical tubes
- 5% CO2 incubator at 37°C, saturating relative humidity
- Class A2 biological safety counter
- Cell counter or hemocytometer
- Flow Cytometer
Growth Media Preparation
- To generate 1 liter of complete OptiPEAK T Lymphocyte, thaw one OptiPEAK T Lymphocyte Protein Supplement in a 37°C water bath. Do not subject the Protein Supplement to multiple freeze-thaw cycles.
- Once the supplement is completely thawed, gently mix the supplement by gently pipetting up and down. Do not vortex.
- Add 100 mL from the OptiPEAK T Lymphocyte Protein Supplement directly to the OptiPEAK T Lymphocyte Base Media.
- This medium requires the supplementation of 10ng/mL recombinant IL-2 or equivalent per desired application. This medium contains HEPES and glutamine source.
- If desired, add gentamicin/amphotericin B (Life Technologies #R01510) at 0.1 to 0.5x final concentration. Do not add to 1x final concentration.
- Once mixed, avoid repetitive heating and cooling of the complete medium. Instead, withdraw and prewarm only the volume needed for the specific procedure.
Plate Set up
- In a 12-well plate, add one mL of each media into appropriate
- Place plate in incubator for
Human T-Cell Isolation
- Acquire 8-10 mL of fresh whole blood from two different healthy human donors.
- Add T-Cell Enrichment cocktail (50 μL per 1 mL of blood) to sample and incubate at room temperature for 20 minutes .
- Transfer blood sample to a 50 mL tube.
- Rinse the blood sample tube with an equal volume of dPBS and combine rinsate with blood sample. Final volume will be approximately 20 mL.
- In a separate tube, prepare 15 mL of gradient density medium and slowly layer PBS- diluted blood sample on top.
- Centrifuge at 2600 RPM for 20 minutes with brake off. Allow centrifuge to come to a full rest.
- Harvest the T-cell enriched buffy coat (the “fuzzy” cell layer at the density gradient interface) with a serological pipette and transfer to a new 50 mL conical tube.
- Fill new tube to top with dPBS to wash enriched cells. Centrifuge at 1400 RPM for 10 minutes with brake on low.
- Discard supernatant and repeat washing steps for a total of two washes. Resuspend cells in 450 μL dPBS.
- Count cells in triplicate using a cell counter or equivalent.
- Calculate the volume of Human T-Activator CD3/CD28 beads necessary to achieve a ratio of 1 bead per cell .
- Add volume of Human T-Activator CD3/CD28 beads to volume of cells
- Equally distribute activated cells between each media condition across donors.
- Place the plate in the incubator.
- Expand cells for 7 days, doubling media volume every other
- Harvest cells on Day 7 and Stain for phenotypic markers.
Results and Discussion
Mean-fold expansion of cells in OptiPeak T Lymphocyte blood-free media was comparable to cells in 5% human serum and greater than cells in 10% fetal bovine serum (Figure 1A). Cells maintained in OptiPeak T lymphocyte blood-free media also showed CD4+ and CD8+ ratios comparable to cells grown in human and bovine serum (Figure 1B). These results show OptiPeak T Lymphocyte blood-free medium’s potential as a viable and regulatory-friendly option for T cell immunotherapy manufacturing.
Written by Atherly Pennybaker
Atherly Pennybaker is a Product Applications Scientist with InVitria. At InVitria she enjoys leveraging her scientific background to help customers successfully transition to blood-free, chemically defined systems. Prior to InVitria, she received a Bachelor of Science in Chemical and Biological Engineering from Colorado State University. During her time there, she conducted undergraduate research in tissue engineering where she co-authored a paper on the osteoinductivity of an engineered biomimetic periosteum. She also worked on the design of a natural cell and tissue scaffold by means of electrospinning demineralized bone matrix.